ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Adiponectin, which exerts marked insulin-sensitizing and anti-inflammatory effects (21), has been reported to be involved in the pathogenesis of non-alcoholic fatty liver, and a previous study demonstrated that a decrease in adiponectin levels is an independent risk factor of developing NAFLD (22, 23).